NCT04822376: Prophylaxis Vaccine Antibodies Ebola
- State
- State not given
- Phase
- Phase 2
- People
- 250 planned
- Started
- 17 Oct 2021
- Primary completion
- Apr 2022
- Arms
- High risk arm, High risk arm (Immunological ancillary study)
- Results
- None posted
- 30 Mar 2021: Trial registered